BiotechTube
Home/PRISM Biolabs/Hyi-Man Park, Ph.D.
HP

Hyi-Man Park, Ph.D.

Director, Research and Development Department

PRISM Biolabs

Therapeutic Areas

Oncology

PRISM Biolabs Pipeline

DrugIndicationPhase
E7386Oncology (undisclosed)Phase 1
PRI-724Undisclosed (β-catenin/CBP inhibitor)Phase 1

Leadership Team at PRISM Biolabs

DT
Dai Takehara
President & CEO
View full PRISM Biolabs profile